
    
      This study is a randomized double blind, sham controlled study to evaluate the safety and
      efficacy of H1-coil rTMS as a treatment for patients over 60 years of age with major
      depressive disorder who have not tolerated or failed to respond to antidepressant
      medications. The study duration is 4-6 weeks in length. The acute phase is 4 weeks of 5 daily
      treatments followed by 2 weeks of biweekly treatment if remission is achieved at the 4 week
      mark. Symptom change and remission criteria will be assessed using the HRDS-24 item.
      Cognition will be assessed using a validated battery.
    
  